HTDS - Hard to Treat Diseases (PINK)

[Spot]

HTDS is a piece of **** (POS) you are well advised to stay away from!

[shockdragon]

Petroflow Energy Ltd. announces subsidiaries' reorganization filings under United States Bankruptcy Code
SHENZHEN, China, July 6 /PRNewswire-FirstCall/ - Hard to Treat Diseases, Inc. (HTDS;
Welcome to HTDS Medical) and Shenzhen Mellow Hope (www.mellowhope.com) are excited to announce
that the company has secured a new business partner in Ethiopia through which Mellow Hope will
distribute biomedical vaccines.
"We anticipate that our new Ethiopian partner will provide Mellow Hope with more business
opportunities in that country, which will certainly improve the company's annual performance,"
said Terry Yuan, president of HTDS. "Furthermore, it is our hope that this partnership will be
only the beginning in the expansion of HTDS and Mellow Hope vaccinations into other African
markets."
China's trade in biomedical vaccines increased 20% between 2008 and 2009. At the same time,
thanks to China's competitive pricing, trade between China and African countries has increased
more than sevenfold since 2000. With diseases like H1N1, SARS, and avian flu requiring widespread
immunization, the global vaccine market is expected to grow 18% annually to a value of $300
billion USD in 2011.
Shenzhen Mellow Hope specializes in biological vaccines such as influenza, Hepatitis A & B, and
Meningococcal Polysaccharide.
The company reminds its shareholders and followers to monitor PinkSheets.com Filing section and
also our IR company web site section "PRESS RELEASES AND FILINGS" TAB
http://www.minamargroup.net/ for non newsworthy corporate updates.
For any matters relating to retail investor queries or to send the company or its IR a message
please click on the "INVESTOR SUPPORT" TAB, or the direct link
The MinaMar Marketing Helpdesk. In this regard, Mina Mar Group works diligently to answer
and address all the pressing issues regarding its clients to the shareholders' satisfaction. MMG
is in constant contact with the companies, addressing, obtaining and processing all inquiries. MMG
is often one of the advisors or IR companies utilized by the issuer. Depending on the location of
the issuer and management's availability, it may take up to several days to address any pressing
issues. In a normal course of business and a pending transaction, the issuer may opt to remain
silent in order not to lose advantage to a competitor. MMG is mindful that sometimes shareholders
want answers immediately, which for the above reasons cannot be fulfilled on a timely basis.
Don't be a victim. Report a stock basher to authorities. The company is mindful that short
sellers, the company competitors and stock bashers stalk small cap Pink Sheets listed companies
with hidden agendas. Visit Exposing Stock Bashers and find out what criminal and civil
actions the US authorities are taking against web sites and the remedies available to you as an
individual investor. Discover for yourself why and how USA based small businesses and the
backbone of the economy suffer. Stay informed and do not allow entrepreneurs dreams, innovations,
and their access to capital to be thwarted as "scalpers" and day traders vigorously day in and day
out try to exploit and extinguish US innovation and progress for quick profits.
Filings for this event are currently being reviewed and will be filed with Pink Sheets and Client
Support section in due course. To be included in company's email database for press releases,
industry updates, and non-weekly activity in the company that may or may not be news released,
please subscribe or opt in mailer at MinaMarGroup - International financial consulting firm and reverse merger transaction specialists..
Safe Harbor Statement
Information in this news release may contain statements about future expectations, plans,
prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking
statements for purposes of the Safe Harbor Provisions under the Private Securities Litigation
Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed,"
"estimate," "project" and similar words and phrases are intended to identify such forward-looking
statements. Hard to Treat Diseases, Inc. cautions you that any forward-looking information
provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance.
None of the information in this press release constitutes or is intended as an offer to sell
securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may
differ materially from those anticipated in such forward-looking statements as a result of various
important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to
those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements
by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat
Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat
Diseases, Inc.'s ability to raise additional capital to fund future operations, Hard to Treat
Diseases, Inc.'s ability to repay its existing indebtedness, the uncertainties involved in
estimating market opportunities, and in identifying contracts which match Hard to Treat Diseases,
Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as
of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake
any obligation to publicly update any forward-looking statement to reflect events or circumstances
after the date on which any such statement is made or to reflect the occurrence of unanticipated
events.
CONTACT: Hard to Treat Diseases, Inc., The MinaMar Marketing Helpdesk
SOURCE Hard to Treat Diseases

Hard to Treat Diseases, Inc., The MinaMar Marketing Helpdesk

[shockdragon]

Axia Group Inc. (AGIJ) Seeks to Acquire (HTDS) Subsidiary Collagenna Skin Care Division

FRANKFURT, Germany, July 12 /PRNewswire-FirstCall/ - Axia Group Inc. (PK: AGIJ) announces that the company entered into negotiations with HTDS for the purchase of its subsidiary Collagenna Skin Care.
AGIJ recently entered into talks with Hard to Treat Diseases (PK: HTDS). HTDS is currently looking for buyers for the company's subsidiary Collagenna, in order to raise capital and continue with its aspirations of a previously announced share buy back program. AGIJ had initiated the Due Diligence on Collagenna and is satisfied with the revenues and prospective growth offered by Collagenna. HTDS is completing the divestiture with Collagenna due to internal restructuring, share buy back and legal matters, and in order to hone their portfolio.
This purchase of assets from HTDS will occur in parallel to a proposed second merger with an EU-based medical company. AGIJ is in the process of arranging financing to finance this purchase, and will inform shareholders on progress on this front.
A source close to the company commented that AGIJ is very impressed thus far with Collagenna, and is excited by the opportunity to acquire the company.
Collagenna Skin Care Products is a natural health products and cosmetics company. Their main products provide anti-aging skin care solutions that visibly repair and rejuvenate on the surface, and from the inside out, by unlocking the beneficial effects of collagen.
The skin care market is growing. In 2007, the industry grew by 4.1% and reached a value of $49.5 billion. Forecasts calculate a market value of $58.2 billion by 2012. Anti-aging products represent 62% of the prestige facial skin care market in 2009, with an estimated worth of $1.2 billion.
Safe Harbor Statement
Information in this news release may contain statements about future expectations, plans, prospects or performance of Axia Group Inc. that constitute forward-looking statements for purposes of the Safe Harbor Provisions under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be", "expects", "may affect", "believed", "estimate", "project" and similar words and phrases are intended to identify such forward-looking statements. Axia Group Inc. cautions you that any forward-looking information provided by or on behalf of Axia Group Inc. is not a guarantee of future performance. None of the information in this press release constitutes or is intended as an offer to sell securities or investment advice of any kind. Axia Group Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Axia Group Inc.'s control. In addition to those discussed in Axia Group Inc.'s press releases, public filings, and statements by Axia Group Inc.'s management, including, but not limited to, Axia Group Inc.'s estimate of the sufficiency of its existing capital resources, Axia Group Inc.'s ability to raise additional capital to fund future operations, Axia Group Inc.'s ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities, and in identifying contracts which match Axia Group Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Axia Group Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
CONTACT: Axia Group Inc.
SOURCE Axia Group Inc.

[shockdragon]

SHENZEN, China, July 13 /PRNewswire-FirstCall/ - Hard to Treat Diseases, Inc. (HTDS; Welcome to HTDS Medical) is pleased to share that HTDS is currently involved in discussions regarding a divestiture of subsidiary Collagenna.
In a company filing on June 23, 2010, HTDS reported legal recommendations pertaining to resolving the company's Caveat Emptor (skull and bones) ranking with Pink Sheets. The consulted securities lawyer suggested a divestiture with Collagenna to simplify HTDS' corporate structure. Following these recommendations, HTDS began the process of looking for a buyer for Collagenna. Axia Group Inc. (PK:AGIJ), a business holding company, expressed interest in purchasing Collagenna, since it is currently seeking viable merger candidates. HTDS is pleased to announce that negotiations have begun on this matter.
HTDS, management is of the opinion that, "This is a mutually beneficial divestiture arrangement. Collagenna is a very valuable company, with tremendous growth and global distribution opportunities, but is perhaps better suited in another company. Our board believes that this divestiture will strengthen shareholder value of HTDS. Investors and followers are keen on HTDS' commitment to medical technology and research and we intend to foster this keenness."
The company reminds its shareholders and followers to monitor PinkSheets.com Filing section and also our IR company web site section "PRESS RELEASES AND FILINGS" TAB http://www.minamargroup.net/ for non newsworthy corporate updates.
For any matters relating to retail investor queries or to send the company or its IR a message please click on the "INVESTOR SUPPORT" TAB, or the direct link The MinaMar Marketing Helpdesk. In this regard, Mina Mar Group works diligently to answer and address all the pressing issues regarding its clients to the shareholders' satisfaction. MMG is in constant contact with the companies, addressing, obtaining and processing all inquiries. MMG is often one of the advisors or IR companies utilized by the issuer. Depending on the location of the issuer and management's availability, it may take up to several days to address any pressing issues. In a normal course of business and a pending transaction, the issuer may opt to remain silent in order not to lose advantage to a competitor. MMG is mindful that sometimes shareholders want answers immediately, which for the above reasons cannot be fulfilled on a timely basis.
Don't be a victim. Report a stock basher to authorities. The company is mindful that short sellers, the company competitors and stock bashers stalk small cap Pink Sheets listed companies with hidden agendas. Visit Exposing Stock Bashers and find out what criminal and civil actions the US authorities are taking against web sites and the remedies available to you as an individual investor. Discover for yourself why and how USA based small businesses and the backbone of the economy suffer. Stay informed and do not allow entrepreneurs dreams, innovations, and their access to capital to be thwarted as "scalpers" and day traders vigorously day in and day out try to exploit and extinguish US innovation and progress for quick profits.
Filings for this event are currently being reviewed and will be filed with Pink Sheets and Client Support section in due course. To be included in company's email database for press releases, industry updates, and non-weekly activity in the company that may or may not be news released, please subscribe or opt in mailer at MinaMarGroup - International financial consulting firm and reverse merger transaction specialists..
Safe Harbor Statement
Information in this news release may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the Safe Harbor Provisions under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be", "expects", "may affect", "believed", "estimate", "project" and similar words and phrases are intended to identify such forward-looking statements. Hard to Treat Diseases, Inc. cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this press release constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, Hard to Treat Diseases, Inc.'s ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities, and in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
CONTACT: For any investor relations matters please contact, www.minamargroup.net/helpdesk; Investor Relations Department Inquiry, www.minamargroup.net (IR); For (M&A) and Corporate Matters, MinaMarGroup - International financial consulting firm and reverse merger transaction specialists.
SOURCE Hard to Treat Diseases

[shockdragon]

BELGRADE, SERBIA -- 07/22/10 -- Hard to Treat Diseases, Inc. (PINK SHEETS: HTDS) Welcome to HTDS Medical) is pleased to announce that researchers from its Slavica BioChem (Homepage | Slavica Biochem) division established the cooperation with world-leading market analysis company from UK.
Dr. Sanja Pekovic, Chief Project Scientist of HTDS, said, "The Datamonitor Group (Datamonitor | the home of Business Information) is world leader in the business intelligence sector. We expect that the multiple sclerosis and traumatic brain injury pipeline and unmet analysis needs of these two markets, prepared by Datamonitor's healthcare and pharmaceutical analysis team, will provide us with insight into most recent findings in order to be a step ahead to our competitors. After getting permission, complete material comprising of clinical opinion, leader intelligence, best-in-class case studies, R&D pipeline, unmet need analysis, scenario-based revenue, epidemiology forecasting, a slide pack and a data pack covering seven major markets (US, France, Germany, Italy, Spain, UK, and Japan) will be available at the HTDS (Welcome to HTDS Medical) and Slavica BioChem (Homepage | Slavica Biochem) web sites.

About Mina Mar Group:

Mina Mar Group (MMG) is a corporate consultancy firm that specializes in small cap or OTC market business services, including public markets in Frankfurt, Germany, and the UK. We provide our clients with comprehensive advisory and consulting services regarding mergers and acquisitions, including reverse mergers of private companies into publicly traded entities, and special purpose companies (SPC) offshore. MMG also offers a full suite of related ancillary services subsequent to the successful completion of a reverse merger, including private placements, Pink Sheets Adequate Disclosure documentation, various SEC regulatory filings and a broad range of other corporate governance matters. Mina Mar Marketing Group, MMMG (Investor relations firm offering a complete range of Investor relations services and consulting), offers publicly traded companies full array of services such as Investor Relations and maintenance investor awareness. Mina Mar Group pioneered the "Go Public Free" program, the first firm to challenge the short sellers, stock bashers and repeal of the "Communication Decency Act". Visit www.minamargroup.com/ice to learn more.

Filings for this event are currently being reviewed and will be filed with Pink Sheets and Client Support section in due course. To be included in company's email database for press releases, "Friday Tips" industry updates, and non-weekly activity in the company that may or may not be news released, please subscribe for opt in mailer at MinaMarGroup - International financial consulting firm and reverse merger transaction specialists..

Safe Harbor Statement

Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

Contacts:
For medical and scientific dialogue inquiry only,
please contact medicalinfo@htdsmedical.com

For any corporate matters,
please contact The MinaMar Marketing Helpdesk

[shockdragon]

SHENZEN, CHINA, Nov 12, 2010 (MARKETWIRE via COMTEX) -- Hard to Treat Diseases, Inc. (HTDS 0.00, +0.00, +20.00%) (Welcome to HTDS Medical) is targeting a merger with a Canadian biotechnology company that deals with blood transfusion products.

This biotechnology company, who wishes to remain anonymous at this stage of negotiations, is a biotechnology company that is involved in validating a product that will reduce the major side effects related to transfusions of donated blood or hemoglobin based blood substitutes. The market value for blood transfusions on the North American market is currently in excess of $14 billion USD.

There is currently a shortfall of blood available for transfusions. Serious harmful side effects exist in the use of stored donor blood; specifically, the loss of Nitric Oxide (NO) from the recipients' blood creates a hazardous condition known as vasoconstriction. Due to the demand for blood and associated transfusions, there are an increasing number of clinical trials and process being developed to counteract the loss of NO from blood.

This up-and-coming biotech company plans to demonstrate in pre-clinical tests that its product can circumvent the loss of NO from blood and improve the shelf life of stored blood for up to 42 days.

HTDS has remained silent for the past several months as it worked on this deal is pleased with this merger opportunity and feels that it may be a perfect fit alongside their current medical subsidiaries Shenzhen Mellow Hope Pharm Industrial Co., Ltd. and Slavica Biochem.

HTDS expects to be in a position to release the name of the merger candidate and the new appointee officers and all relevant data shortly. The company is of the opinion that this is a significant event that requires a public release.

More details to follow shortly.

About Mina Mar Group:

Mina Mar Group pioneered the "Go Public Free" program, the first firm to challenge the short sellers, stock bashers and repeal of the "Communication Decency Act". Visit www.minamargroup.com/ice to learn more.

Mina Mar Marketing Group, MMMG (Investor relations firm offering a complete range of Investor relations services and consulting) offers publicly traded companies a full array of services such as Investor Relations and maintenance investor awareness.

To be included in company's email database for press releases, "Friday Tips", industry updates, and company activity that may or may not be news released, please subscribe for opt-in mailer at MinaMarGroup - International financial consulting firm and reverse merger transaction specialists..

Safe Harbor Statement

Information in this news release may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases Inc., that constitute forward-looking statements for purposes of the Safe Harbor Provisions under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project" and similar words and phrases are intended to identify such forward-looking statements. Hard to Treat Diseases Inc. cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases Inc. is not a guarantee of future performance. None of the information in this quarterly report constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases Inc.'s control. In addition to those discussed in Hard to Treat Diseases Inc.'s press releases, public filings, and statements by Hard to Treat Diseases Inc.'s management, including, but not limited to, Hard to Treat Diseases Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases Inc.'s ability to raise additional capital to fund future operations, Hard to Treat Diseases Inc.'s ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities, and in identifying contracts which match Hard to Treat Diseases Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.


Contacts:
Investor Relations:
http://www.minamargroup.net/helpdesk...rgroup.comHard to Treat Diseases Inc.: crobichaud@htdsmedical.com





SOURCE: Hard to Treat Diseases, Inc.

http://www.minamargroup.net/helpdesk...tdsmedical.com



Copyright 2010 Marketwire, Inc., All rights reserved.

[shockdragon]

SHENZHEN, CHINA, Nov 19, 2010 (MARKETWIRE via COMTEX) -- Hard to Treat Diseases, Inc. (HTDS 0.00, -.00, -25.00%) (Welcome to HTDS Medical) subsidiary Shenzhen Mellow Hope Pharm Industrial Co., Ltd. (Mellow Hope) has delivered its first BIOVAC-FLU samples to India.

Mellow Hope (Shenzhen Mellow Hope Pharm Industrial Co., Ltd.), the biggest exporter of biological vaccines in China, has delivered a batch of Influenza virus vaccines, Inactivated (Split) (BIOVAC-FLU) to a company in India for sample analysis before beginning the new purchase order. The company expects to finalize the sample analysis within one month. After that a new purchase order will be signed between Mellow Hope and the partner in India. That is the first batch of BIOVAC-FLU exported to India in 2010.

Mellow Hope is pleased with this agreement and hopes that this will provide new opportunities for growth.

Safe Harbor Statement

Information in this news release may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases Inc., that constitute forward-looking statements for purposes of the Safe Harbor Provisions under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project" and similar words and phrases are intended to identify such forward-looking statements. Hard to Treat Diseases Inc. cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases Inc. is not a guarantee of future performance. None of the information in this quarterly report constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases Inc.'s control. In addition to those discussed in Hard to Treat Diseases Inc.'s press releases, public filings, and statements by Hard to Treat Diseases Inc.'s management, including, but not limited to, Hard to Treat Diseases Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases Inc.'s ability to raise additional capital to fund future operations, Hard to Treat Diseases Inc.'s ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities, and in identifying contracts which match Hard to Treat Diseases Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.


Contacts:
Hard to Treat Diseases, Inc.
corporate@htdsmedical.com





SOURCE: Hard to Treat Diseases, Inc.

mailto:corporate@htdsmedical.com



Copyright 2010 Marketwire, Inc., All rights reserved.

[shockdragon]

SHENZHEN, CHINA, Nov 22, 2010 (MARKETWIRE via COMTEX) -- Hard to Treat Diseases, Inc. (HTDS 0.00, +0.00, +66.67%) (Welcome to HTDS Medical) announces that the merger negotiations with the Canadian Biotechnology company are proceeding well, and that the merger candidate permitted HTDS to release the name and additional information about the candidate:

The merger candidate, Hb Products Inc., is a Canadian biotechnology company that deals with blood transfusion products. Hb Products Inc. is a biotechnology company that is involved in validating a product that will reduce the major side effects related to transfusions of donated blood or hemoglobin-based blood substitutes.

Hb Products Inc. focuses on treatment of serious harmful side effects existing with the use of stored donor blood, focusing specifically on solving the loss of Nitric Oxide (NO) from the recipients' blood, which creates a hazardous condition called vasoconstriction. The market for these blood products is relatively untapped and highly competitive. Due to the potential market for blood substitutes and the shortfall of available donor blood, several pharmaceutical companies have attempted to gain FDA approval for their products, but none have succeeded as of yet. Hb Products Inc. plans to demonstrate in pre-clinical tests that its product can circumvent the loss of NO from blood and improve the shelf life of stored blood for up to 42 days.

The market value for blood transfusions on the North American market is currently in excess of $14 billion USD.

HTDS sees Hb Products as a perfect fit alongside their current medical subsidiaries Shenzhen Mellow Hope Pharm Industrial Co., Ltd. and Slavica Biochem.

Safe Harbor Statement

Information in this news release may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases Inc., that constitute forward-looking statements for purposes of the Safe Harbor Provisions under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project" and similar words and phrases are intended to identify such forward-looking statements. Hard to Treat Diseases Inc. cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases Inc. is not a guarantee of future performance. None of the information in this quarterly report constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases Inc.'s control. In addition to those discussed in Hard to Treat Diseases Inc.'s press releases, public filings, and statements by Hard to Treat Diseases Inc.'s management, including, but not limited to, Hard to Treat Diseases Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases Inc.'s ability to raise additional capital to fund future operations, Hard to Treat Diseases Inc.'s ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities, and in identifying contracts which match Hard to Treat Diseases Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.


Contacts:
Hard to Treat Diseases, Inc.
corporate@htdsmedical.com
Welcome to HTDS Medical




SOURCE: Hard to Treat Diseases, Inc.

[shockdragon]

SHENZHEN, CHINA, Nov 26, 2010 (MARKETWIRE via COMTEX) -- Hard to Treat Diseases, Inc. (HTDS 0.00, 0.00, 0.00%) (Welcome to HTDS Medical) subsidiary Shenzhen Mellow Hope Pharm Industrial Co., Ltd. (Mellow Hope) announces that, after four years of continuous effort, the registration of Cerebroprotein Hydrolysate for Injection (Cognistar) has been approved by India's drug regulator, Drugs Controller General of India (DCGI).

As soon as the approval is finalized, Mellow Hope (Shenzhen Mellow Hope Pharm Industrial Co., Ltd.) will launch this product in the local market. Until this point there has been no local supplier in India for Cognistar, so the company anticipates healthy sales as it fills this market vacancy and claims a large market share. The company received permit to import this product to India, and copy of this certificate will be made available @ Welcome to HTDS Medical. The company will also post this certificate on OTCMarkets.Com as a filing shortly.

Cognistar is a unique nutriment for the brain. It regulates and improves nerve cell metabolism, promotes synapse generation, induces nerve cell differentiation, and protects nerve cells against damages by ischemia and neurotoxins.

The company is pleased at this approval after years of diligent research, and will keep the investor public updated as the first batches of Cognistar reach the Indian market.

In other company news and updates, regarding the news of November 22, 2010 and merger progress with a Canadian based Hb Products Inc. (Hb) the company is working diligently and vigorously to have the merger completed way ahead of the Christmas holidays. Currently a new updated web site is being developed to include Hb with a preview available at this link Welcome to HTDS Medical.

The management will release further updates shortly as they become available.

Safe Harbor Statement

Information in this news release may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases Inc., that constitute forward-looking statements for purposes of the Safe Harbor Provisions under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project" and similar words and phrases are intended to identify such forward-looking statements. Hard to Treat Diseases Inc. cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases Inc. is not a guarantee of future performance. None of the information in this quarterly report constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases Inc.'s control. In addition to those discussed in Hard to Treat Diseases Inc.'s press releases, public filings, and statements by Hard to Treat Diseases Inc.'s management, including, but not limited to, Hard to Treat Diseases Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases Inc.'s ability to raise additional capital to fund future operations, Hard to Treat Diseases Inc.'s ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities, and in identifying contracts which match Hard to Treat Diseases Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.


Contacts:
Hard to Treat Diseases Inc.
corporate@htdsmedical.com





SOURCE: Hard to Treat Diseases, Inc.

[shockdragon]

SHENZEN, CHINA -- (MARKET WIRE) -- 03/03/11 -- Hard to Treat Diseases, Inc. (PINK SHEETS: HTDS) (Welcome to HTDS Medical) announced today that its China -based Shenzhen Mellow Hope subsidiary is planning a seminar for Indian medical experts.
The Indian experts are expected in China for the seminar and will visit Chinese medical experts in Beijing , Shanghai and Shenzhen . They will discuss plans to market 'Cognistar' (Cerebroprotein Hydrolysate for Injection) in India . Mellow Hope believes that this product will receive wide acceptance in the Indian market and has huge growth potential.
Mellow Hope finished the clinical trials of Cerebroprotein Hydrolysate for Injection in India . This biological product is a unique nutriment for the brain that helps the central nervous system in multiple ways, including: regulating and improving nerve cell metabolism; promoting synapse generation; inducing nerve cell differentiation; and protecting nerve cells against damages by ischemia and neurotoxins.
Mellow Hope looks forward to the visit from the Indian medical experts and plans to update investors as these developments progress.
Safe Harbor Statement
Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
Contacts:
For medical and scientific dialogue inquiry only,
please contact medicalinfo@htdsmedical.com.


Source: Hard to Treat Diseases, Inc.